[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 26, 2000

Cost-effectiveness of Pneumococcal Vaccine—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;284(4):440-441. doi:10.1001/jama.284.4.436

In Reply: Dr Le observes that no large clinical trials of pneumococcal conjugate vaccine efficacy have been conducted for a single dose catch-up vaccination for children aged 24 to 59 months. We believe that our extrapolation of vaccine efficacy was reasonable based on the input of our study's expert panel of pediatric infectious disease specialists, which made this judgment based on immunogenicity data. Furthermore, a separate expert panel of pediatric infectious disease specialists also has concluded that this assumption is valid based on available data. These data now include a randomized clinical trial of more than 200 children aged 12 to 35 months, which has found that 9-valent pneumococcal conjugate vaccine reduced rates of respiratory infection when given under catch-up protocols.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×